The discomforts that travel with treatment
Sleep benefits deserve enthusiasm. The adverse effects deserve the same attention to detail.
Gastrointestinal effects in the obesity trial
In SURMOUNT-1, adults with obesity or overweight and a weight-related complication, without diabetes, were studied for weight reduction. Gastrointestinal effects were the most common adverse events with tirzepatide, mostly mild to moderate and occurring primarily during dose escalation.
A broader safety review covering tirzepatide and GLP-1 receptor agonists describes nausea, vomiting, diarrhea and constipation as the most common side effects, typically emerging during dose escalation and resolving over time. This wider review brings together several forms of evidence and several treatments; its summary has that broader scope.
“Mild to moderate” is a classification I respect. The inconvenience of a particular day remains harder to describe. An account of treatment that wants credit for a better day has to make room for days disrupted by its adverse effects.
Tolerability is a practical question about continuing treatment.
Gallbladder and pancreatic findings
A meta-analysis of nine randomized trials in type 2 diabetes and obesity found an increased risk for the combined outcome of gallbladder or biliary disease with tirzepatide versus controls: relative risk 1.97, with a 95% confidence interval of 1.14 to 3.42. The controls included basal insulin, selective GLP-1 receptor agonists or placebo.
The individual components of that combined outcome did not show statistically significant increases. Pancreatitis likewise showed no statistically significant increase, with a relative risk of 1.46 and a 95% confidence interval of 0.59 to 3.61. All of these findings come from the same pooled analysis.
I take the combined gallbladder finding seriously. The nonsignificant pancreatitis result leaves the question open. The interval preserves the uncertainty more honestly than an all-purpose safety adjective could.
The withdrawal evidence measures weight
The SURMOUNT-4 randomized withdrawal trial found that continued tirzepatide maintained and augmented weight reduction, while withdrawal led to substantial weight regain in adults with obesity. That is relevant to the effort involved in sustaining weight change.
The sleep papers examined here address different outcomes. A claim about the return of apnea after stopping treatment would require evidence about apnea after stopping treatment. I won’t use the weight-withdrawal result to supply a missing sleep follow-up.
I’m impatient for a sleep follow-up that addresses withdrawal directly. For the present account, the sleep trials establish their own findings, and the withdrawal trial establishes a weight finding. Keeping their subjects clear leaves a more useful picture of the work still ahead.